SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-175032
Filing Date
2023-06-26
Accepted
2023-06-26 16:02:01
Documents
12
Period of Report
2023-06-23
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d477366d8k.htm   iXBRL 8-K 33952
  Complete submission text file 0001193125-23-175032.txt   155760

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA akro-20230623.xsd EX-101.SCH 2851
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20230623_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20230623_pre.xml EX-101.PRE 11262
6 EXTRACTED XBRL INSTANCE DOCUMENT d477366d8k_htm.xml XML 3367
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 231042328
SIC: 2834 Pharmaceutical Preparations